175 related articles for article (PubMed ID: 38086334)
1. ALKemy to enhance chimeric antigen receptor T cell immunotherapy for neuroblastoma.
Ruella M
Cancer Cell; 2023 Dec; 41(12):2016-2018. PubMed ID: 38086334
[TBL] [Abstract][Full Text] [Related]
2. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.
Walker AJ; Majzner RG; Zhang L; Wanhainen K; Long AH; Nguyen SM; Lopomo P; Vigny M; Fry TJ; Orentas RJ; Mackall CL
Mol Ther; 2017 Sep; 25(9):2189-2201. PubMed ID: 28676342
[TBL] [Abstract][Full Text] [Related]
3. Targeting of low ALK antigen density neuroblastoma using AND logic-gate engineered CAR-T cells.
Halliwell E; Vitali A; Muller H; Alonso-Ferrero M; Barisa M; Gavriil A; Piapi A; Leboreiro-Babe C; Gileadi T; Yeung J; Pataillot-Meakin T; Fisher J; Tucker L; Donovan L; Chesler L; Chester K; Anderson J
Cytotherapy; 2023 Jan; 25(1):46-58. PubMed ID: 36396552
[TBL] [Abstract][Full Text] [Related]
4. ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells.
Bergaggio E; Tai WT; Aroldi A; Mecca C; Landoni E; Nüesch M; Mota I; Metovic J; Molinaro L; Ma L; Alvarado D; Ambrogio C; Voena C; Blasco RB; Li T; Klein D; Irvine DJ; Papotti M; Savoldo B; Dotti G; Chiarle R
Cancer Cell; 2023 Dec; 41(12):2100-2116.e10. PubMed ID: 38039964
[TBL] [Abstract][Full Text] [Related]
5. Supercharged chimeric antigen receptor T cells in solid tumors.
Pant A; Jackson CM
J Clin Invest; 2022 Aug; 132(16):. PubMed ID: 35968786
[TBL] [Abstract][Full Text] [Related]
6. CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice.
Li N; Torres MB; Spetz MR; Wang R; Peng L; Tian M; Dower CM; Nguyen R; Sun M; Tai CH; de Val N; Cachau R; Wu X; Hewitt SM; Kaplan RN; Khan J; St Croix B; Thiele CJ; Ho M
Cell Rep Med; 2021 Jun; 2(6):100297. PubMed ID: 34195677
[TBL] [Abstract][Full Text] [Related]
7. CAR T Cell Therapy for Neuroblastoma.
Richards RM; Sotillo E; Majzner RG
Front Immunol; 2018; 9():2380. PubMed ID: 30459759
[TBL] [Abstract][Full Text] [Related]
8. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma.
Tomida A; Yagyu S; Nakamura K; Kubo H; Yamashima K; Nakazawa Y; Hosoi H; Iehara T
Cancer Sci; 2021 Oct; 112(10):4026-4036. PubMed ID: 34382720
[TBL] [Abstract][Full Text] [Related]
10. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
11. GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity.
Heitzeneder S; Bosse KR; Zhu Z; Zhelev D; Majzner RG; Radosevich MT; Dhingra S; Sotillo E; Buongervino S; Pascual-Pasto G; Garrigan E; Xu P; Huang J; Salzer B; Delaidelli A; Raman S; Cui H; Martinez B; Bornheimer SJ; Sahaf B; Alag A; Fetahu IS; Hasselblatt M; Parker KR; Anbunathan H; Hwang J; Huang M; Sakamoto K; Lacayo NJ; Klysz DD; Theruvath J; Vilches-Moure JG; Satpathy AT; Chang HY; Lehner M; Taschner-Mandl S; Julien JP; Sorensen PH; Dimitrov DS; Maris JM; Mackall CL
Cancer Cell; 2022 Jan; 40(1):53-69.e9. PubMed ID: 34971569
[TBL] [Abstract][Full Text] [Related]
12. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
[TBL] [Abstract][Full Text] [Related]
13. Chimeric Antigen Receptor Design Today and Tomorrow.
Boucher JC; Davila ML
Cancer J; 2021 Mar-Apr 01; 27(2):92-97. PubMed ID: 33750067
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor T cell: A cancer immunotherapy.
Singh S; Khasbage S; Kaur RJ; Sidhu JK; Bhandari B
Indian J Pharmacol; 2022; 54(3):226-233. PubMed ID: 35848695
[TBL] [Abstract][Full Text] [Related]
15. Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas.
Muhsen IN; Hill LC; Ramos CA
Hematol Oncol Clin North Am; 2023 Dec; 37(6):1107-1124. PubMed ID: 37357070
[TBL] [Abstract][Full Text] [Related]
16. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
Guedan S; Alemany R
Front Immunol; 2018; 9():2460. PubMed ID: 30405639
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma.
Straathof K; Flutter B; Wallace R; Jain N; Loka T; Depani S; Wright G; Thomas S; Cheung GW; Gileadi T; Stafford S; Kokalaki E; Barton J; Marriott C; Rampling D; Ogunbiyi O; Akarca AU; Marafioti T; Inglott S; Gilmour K; Al-Hajj M; Day W; McHugh K; Biassoni L; Sizer N; Barton C; Edwards D; Dragoni I; Silvester J; Dyer K; Traub S; Elson L; Brook S; Westwood N; Robson L; Bedi A; Howe K; Barry A; Duncan C; Barone G; Pule M; Anderson J
Sci Transl Med; 2020 Nov; 12(571):. PubMed ID: 33239386
[TBL] [Abstract][Full Text] [Related]
18. Opportunities and obstacles for the melanoma immunotherapy using T cell and chimeric antigen receptor T (CAR-T) applications: a literature review.
Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori H; Mansoori Y; Salahi A; Nikfar G; Tavassoli A; Behmard E; Moravej A; Ghasemian A
Mol Biol Rep; 2022 Nov; 49(11):10627-10633. PubMed ID: 35715610
[TBL] [Abstract][Full Text] [Related]
19. Challenges of driving CD30-directed CAR-T cells to the clinic.
Grover NS; Savoldo B
BMC Cancer; 2019 Mar; 19(1):203. PubMed ID: 30841880
[TBL] [Abstract][Full Text] [Related]
20. Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors.
Du X; Darcy PK; Wiede F; Tiganis T
Mol Cell Biol; 2022 Mar; 42(3):e0044921. PubMed ID: 35041491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
